Epstein--Barr virus (EBV), like all members of the human herpesvirus family, persists in the host after primary infection and may reactivate at any time. As EBV may replicate without causing apparent harm, it is important to be able to distinguish asymptomatic infection from impending EBV disease, which is troublesome in teenagers and young adults^[@bib1]^ and is especially serious in the immunocompromised host.^[@bib2]^ There are few data about EBV activity in immunocompetent, asymptomatic adults over time.^[@bib3],\ [@bib4]^ Characterizing viral--host interactions in healthy adults would provide a baseline for defining quantitative thresholds associated with EBV disease. Tracing the stability or variability of EBV strains over time could establish the rate of reactivation as compared with superinfection and could also be used to trace transmission. For these reasons, we performed a 6-month intensive prospective surveillance study in healthy immunocompetent adults.

Results
=======

Characteristics of the study participants
-----------------------------------------

Twelve consecutive volunteers were enrolled and followed for 6 months. Their characteristics on enrollment are given in [Table 1](#tbl1){ref-type="table"}. The subjects completed 97 (90%) of their 108 scheduled visits during which they provided 287 samples for EBV testing (median, 25 samples per subject; mean, 24 samples per subject) ([Table 2](#tbl2){ref-type="table"}). Eleven subjects had been previously infected by EBV and one volunteer was EBV naive. Three of the 11 antibody-positive subjects had positive viral capsid antigen (VCA) IgM enzyme immunoassay (EIA) indices (1.26--5.88). Their antibody profiles reflected recurrent rather than primary infection because all of them had robust EBV nuclear antigen 1 (EBNA-1) antibody levels ([Table 3](#tbl3){ref-type="table"}). Two of these subjects remained VCA IgM positive during the entire trial, whereas one subject became VCA IgM negative after 6 months.

EBV DNA shedding
----------------

EBV DNA was present in 63 (24%) of 260 samples from the 11 antibody-positive adults and in 0 of 27 samples from the EBV naive subject. All antibody-positive participants had EBV DNA detected in at least one oral sample. One subject who was positive for VCA and EBNA IgG antibodies but negative for VCA IgM antibodies throughout the 6-month study had EBV DNA recovered from 17 of 24 samples including 7 of 8 whole-blood specimens. She had EBV DNAemia on seven consecutive visits spanning 79 days (quantitative range, 3.1--3.8 log~10~ copies EBV per ml of whole blood). Considering all subjects, the oral cells contained the highest proportion of detectable EBV DNA, followed by the oral supernatant and whole blood ([Table 2](#tbl2){ref-type="table"}). The subjects fit into two age groups: 18 to 30 years old (five subjects) and \>30 years old (six subjects). The younger group was more likely to have EBV DNA recovered than the older group and the differences in the proportions of positive samples in the oral cell compartment and whole blood were statistically significant ([Table 2](#tbl2){ref-type="table"}). There were no significant differences between older and younger subjects in terms of the average, minimum or maximum quantities of EBV DNA.

EBV strain analysis
-------------------

We chose to compare nucleotide differences in the C terminus of the EBV latent membrane protein (LMP)-1 gene to characterize our subjects\' EBV strains because the region has been shown to be highly variable^[@bib5]^ and this approach was used successfully by van Kooij *et al.*^[@bib6]^ to define patterns of sequence variation in healthy individuals and patients with postransplant lymphoproliferative disorder.

LMP-1 sequence variation analysis was performed on 31 selected samples from the 11 antibody-positive subjects ([Figure 1](#fig1){ref-type="fig"}). For subjects who shed EBV on more than one visit, samples were chosen as far apart in time as possible. Specimens containing as few as 160 copies per ml of sample could be sequenced. We were able to identify the LMP-1 sequences from all antibody-positive patients. The EBV LMP-1 sequences of the subjects fit into five patterns. Pattern 5 was the most common, being found in 6 of the 11 volunteers. Six subjects had LMP-1 sequences analyzed from more than one compartment or time point. Of the 26 samples sequenced from these subjects, 23 (88%) were identical and 3 contained only 2 positional mismatches. Ten subjects harbored EBV EBNA-2 type 1 virus and one (subject 210) had EBV EBNA-2 type 2 virus.

Discussion
==========

All 11 healthy adults previously infected by EBV had EBV DNA detected in at least one oral sample during the 6-month observation period. The five subjects in the 18--30-year-old group (age range, 20--25 years) had significantly more EBV-positive samples than the 6 subjects over 30 (age range, 30.3--64 years). Also, the only viremic subject was in the younger age group. Interestingly, she was negative for VCA IgM antibodies throughout the 6-month study. We speculate that the frequency of EBV DNA shedding in asymptomatic immunocompetent hosts steadily declines with time after primary infection. Thus, the greater EBV shedding among younger subjects may reflect a shorter time from their primary EBV infection to sampling. Although the quantity of EBV DNA in these asymptomatic subjects was generally less than that reported in patients with infectious mononucleosis,^[@bib1]^ chronic active EBV infection^[@bib7]^ or transplant recipients.^[@bib8]^ However, 4.0 log~10~ copies EBV per ml were present in 6 (18%) of 34 oral cell pellet samples, and in 3 (14%) of 22 oral supernatant samples. The viremic subject had \>3.0 log~10~ copies EBV per ml in seven consecutive blood samples over 79 days. This should be considered when attempting to associate the quantity of EBV DNA in certain compartments with its pathogenic potential and evaluating the need for a therapeutic intervention.

Our findings are consistent with two previous reports of EBV shedding in healthy antibody-positive subjects.^[@bib3],\ [@bib4]^ However, our study differs in that our subjects were sampled more frequently (nine times in 6 months), there was a significantly higher prevalence of samples positive for EBV DNA among younger subjects, and there was no difference in the proportion of positive samples during any of the 6 months studied (data not shown).

EBV strain identification based on the LMP-1 sequence patterns revealed a single EBV strain in every healthy antibody-positive individual. Of the 11 subjects tested, five unique patterns of LMP-1 were identified, ranging from variants similar to the B95-8 strain to strains that included the 30-bp deletion ([Figure 1](#fig1){ref-type="fig"}). For subjects with EBV DNA detected in multiple compartments, the LMP-1 sequences were nearly identical and these sequences did not change over time. We postulate that the LMP-1 sequence identified for each subject was the dominant strain.

Although we have not detected mixtures with our method, other groups have regularly reported multiple strain infections from asymptomatic carriers with a varying degree of prevalence. Walling *et al.*^[@bib9]^ detected multiple strains in two of nine healthy adults using a direct LMP-1 amplification genotyping method. Within these two patients, they noted compartmental differences between the oral cavity and peripheral blood, as well as temporal changes. Using a highly sensitive heteroduplex tracking assay of the LMP-1 gene locus, Sitki-Green *et al.*^[@bib10]^ found mixtures in 20 of 20 asymptomatic carriers. As many as six different variants were reported in some subjects. Sixteen of the 20 subjects exhibited differences between their oral wash and peripheral blood at a given time. However, other investigators such as Meijer *et al.*^[@bib11]^ have not observed EBV strain differences in body compartments. Most likely, the differences are methodological.

The importance of minority variants in EBV epidemiology has yet to be defined.^[@bib12]^ It could be that minority variants evolve from an individual\'s viral swarm over time and do not signify acquisition of exogenous strains. We believe that detecting the dominant strain is advantageous for providing information regarding the source of the subject\'s EBV infection. The similarity of the LMP-1 sequence pattern in different body compartments in the same subject and its apparent stability over time suggest that our method of LMP-1 sequencing could prove to be a powerful tool for investigating person-to-person transmission. As an example, we recently reported that this method confirmed donor to recipient transmission of EBV during pediatric kidney transplantation.^[@bib13]^

Methods
=======

Clinical trial design
---------------------

Healthy consecutively acquired volunteers ⩾18 years old were seen nine times over a 6-month period (twice weekly for 3 weeks, and once at 6, 12 and 24 weeks). A brief medical history was obtained at the time of enrollment. At every visit, venous blood and oral washes were collected as previously described.^[@bib14]^ This study was approved by the Research Subjects Protection Program of the University of Minnesota, and subjects gave written informed consent before participation.

Quantitation of EBV DNA in oral washes and blood
------------------------------------------------

A real-time TaqMan PCR assay was used to quantitate EBV in whole blood, oral cells and oral supernatant samples collected at every visit.^[@bib14]^ The amplicon for the quantitative EBV assay was a 71-bp portion of the *EBNA-1* gene. The forward primer was: 5′-GAC TGT GTG CAG CTT TGA CGA T-3′ the reverse primer was: 5′-CGG CAG CCC CTT CCA-3′ and the probe was: 5′-(FAM) TAG ATT TGC CTC CCT GGT TTC CAC CTA TG-(TAMRA)-3′. Quantitative EBV data were expressed as viral copies per ml of oral wash or whole blood. The reliable limit of detection of the assay was 4 copies/reaction, which equates to 16 copies per ml for the oral wash fluid-derived cell pellet and 80 copies per ml for the oral wash fluid-derived supernatant and the whole blood.

EBV antibody tests and classification of EBV infection
------------------------------------------------------

EBV antibody assays were performed on serum samples collected on enrollment and at 6, 12 and 24 weeks using commercially available enzyme immunoassay (EIA) kits and a MAGO Plus Automated EIA Processor (Diamedix Corporation, Miami, FL, USA). Results were expressed as the index value, which was the absorbance of the patient\'s sample divided by the mean absorbance of three replicate dilutions of a weakly positive control supplied by the manufacturer. The results were classified according to their index value as: negative, \<0.90; equivocal, 0.90--1.09; and positive, ⩾1.10.

The stage of EBV infection was defined by the following antibody profiles: past infection, positive for IgG antibodies against both EBV VCA and EBNA-1, and negative for IgM antibodies against VCA; recurrent infection, positive for VCA IgM, VCA IgG, and EBNA-1 IgG; and naive to EBV, negative for VCA IgM, VCA IgG, and EBNA-1 IgG.

LMP-1 sequence variation and EBNA-2 typing
------------------------------------------

The primers used for determining LMP-1 sequence variation and EBNA-2 typing are listed in [Table 4](#tbl4){ref-type="table"}. The LMP-1 primers were those of van Kooij *et al.*^[@bib6]^ with modifications. The EBNA-2 primers were those described by Higa *et al.*^[@bib15]^ with minor modifications. PCR was performed in an ABI 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA). The program consisted of 1 cycle at 95 °C for 10 min, 40 cycles at 95 °C for 30 s, 55 °C for 30 s, 72 °C for 60 s, followed by 72 °C for 10 min after which the temperature was reduced to 4 °C and held. PCR products were run in a 1% agarose gel. The Namalwa cell line (ATCC CRL1422), which contains two integrated copies of EBV per cell,^[@bib16]^ was used as the positive control and the negative control contained no template. EBNA-2 genotyping was based on the nested PCR product size: type 1 was 497 bp and type 2 was 162 bp. LMP-1 PCR products were purified with a QIAquick PCR Purification Kit (Qiagen, Valencia, CA, USA). Purified PCR products were sequenced by the University of Minnesota\'s Advanced Genetic Analysis Center using an ABI 3100 DNA sequencer and Big Dye chemistry (Applied Biosystems, Foster City, CA, USA). Chromatograms were compared with the EBV B95-8 reference strain using the Sequencher program (Gene Codes, Ann Arbor, MI, USA).

Statistics
----------

Differences in proportions of samples positive for EBV DNA were compared using the Fisher\'s exact test. Two-sided *P-*values \<0.05 were considered significant. Differences in the subject average, minimum and maximum EBV DNA values between subjects 18--30 years of age versus those \>30 years old were examined using an unpaired *t*-test. Similarly, differences between males and females were tested. Significance was determined using a two-tailed *P*-value \<0.05. Statistics were performed using GraphPad InStat version 3.0, GraphPad Software, San Diego, CA, USA.

This study was approved by the Research Subjects Protection Program of the University of Minnesota, and subjects gave written informed consent before participation. The research was supported by grants from the University of Minnesota Foundation and the University of Minnesota International Center for Antiviral Research and Epidemiology (I CARE).
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![Five LMP-1 sequence patterns of EBV strains from 11 subjects. The symbol / indicates regions where nucleotides could not be determined. The symbol \* denotes positional mismatches from a subject\'s other samples. Letters indicate nucleotides that differ from the B95-8 sequence. OC, oral cell compartment sample; OS, oral supernatant sample; WB, whole-blood sample; ins, insertion; del, deletion.](cti201628f1){#fig1}

###### Characteristics of the 12 subjects on enrollment

  *Characteristic*                                                                       
  -------------------------------------------------------------------------------------- -----------------------------------
  Age in years---median (mean, range)                                                    28.4 (33.7, 20--64)
  Women---no. (%)                                                                        8 (75)
  History of infectious mononucleosis (%)                                                2 (17)[a](#t1-fn2){ref-type="fn"}
                                                                                          
  *EBV infection status defined by profile of VCA IgG, VCA IgM, EBNA-1 IgG antibodies*   
   Past (positive for VCA and EBNA-1 IgG only)                                           8
   Recurrent (positive for all three antibodies)                                         3
   Naive (negative for all three antibodies)                                             1

Abbreviations: EBV, Epstein--Barr virus; EBNA-1, EBV nuclear antigen 1; VCA, viral capsid antigen.

One of the two cases was laboratory confirmed.

###### EBV DNA shedding pattern, proportion of positive samples and amount of EBV DNA detected by age group in antibody-positive subjects

                                                                                *Subjects 18--30 years old*                *Subjects \>30 years old*              *All subjects*
  ---------------------------------------------------------------------- ----------------------------------------- ----------------------------------------- -------------------------
  Number of subjects                                                                         5                                         6                                11
  Mean age (range)                                                                     22.5 (20--25)                             44.3 (30--64)                     34.4 (20--64)
                                                                                                                                                                          
  *Antibody profile*                                                                                                                                         
   Past EBV infection                                                                        3                                         5                                 8
   Recurrent EBV infection                                                                   2                                         1                                 3
  Subjects positive at least once                                                            5                                         6                                11
  Subjects viremic                                                                           1                                         0                                 1
                                                                                                                                                                          
  *Proportion of positive samples*                                                                                                                           
   Oral cells                                                             19/36 (53%)[a](#t2-fn2){ref-type="fn"}    15/51 (29%)[a](#t2-fn2){ref-type="fn"}          34/87 (39%)
   Oral supernatant                                                                     12/36 (33%)                               10/51 (20%)                       22/87 (25%)
   Whole blood                                                             7/36 (19%)[b](#t2-fn3){ref-type="fn"}     0/50 (0%)[b](#t2-fn3){ref-type="fn"}            7/86 (8%)
   All samples                                                            38/108 (35%)[c](#t2-fn4){ref-type="fn"}   25/152 (16%)[c](#t2-fn4){ref-type="fn"}        63/260 (24%)
                                                                                                                                                                          
  *Median log*~*10*~*copies EBV DNA in positive samples (mean, range)*                                                                                       
   Oral cells                                                                     3.69 (3.49; 1.70--4.91)                   3.08 (2.92; 1.70--3.88)           3.50 (3.24; 1.70--4.91)
   Oral supernatant                                                               3.30 (3.47; 3.00--4.25)                   3.50 (3.51; 3.00--4.25)           3.36 (3.49; 3.00--4.25)
   Whole blood                                                                    3.30 (3.39; 3.08--3.79)                             ---                     3.30 (3.39; 3.08--3.79)

Abbreviation: EBV, Epstein--Barr virus.

*P*=0.04, Fisher\'s exact test.

*P*=0.002, Fisher\'s exact test.

*P*\<0.001, Fisher\'s exact test.

###### EBV antibody profile of subjects positive for VCA IgM antibody on enrollment

  *Subject (age and sex)*   *Enrollment*   *Final visit*[a](#t3-fn3){ref-type="fn"}                        
  ------------------------- -------------- ------------------------------------------ ------ ------ ------ ------
  205 (25.1 F)              1.26           5.36                                       3.99   0.64   5.18   4.93
  208 (30.3 F)              5.88           5.41                                       4.27   2.95   5.49   7.51
  212 (20.7 F)              2.32           2.89                                       6.45   1.81   3.47   3.45

Abbreviations: EBNA-1, EBV nuclear antigen 1; F, female; VCA, viral capsid antigen.

EIA index interpretation: negative, \<0.90; equivocal, 0.90--1.09; and positive, ⩾1.10.

205, study day, 168; 208, study day 168; 212 study day, 90.

###### Primers used for LMP-1 sequence analysis and EBNA-2 typing

                                           *Primer sequence*                             *Nested PCR run*
  ---------------------------------------- -------------------------------------------- ------------------
  *LMP-1 primers*                                                                       
   LMP-168843R                             CTACAACAAAACTGGTGGACT                             1st PCR
   LMP-168039F                             AGACAGTGTGGCTAAGGGAGT                                 
   LMP-168810R                             CTCCTTTGGCTCCTCCTGTT                              2nd PCR
   LMP-168039F                             AGACAGTGTGGCTAAGGGAGT                                 
   LMP-168689R or LMP-168390R              CTGGCCATGAATCTGACTCT AGCGACTCTGCTGGAAATGAT        3rd PCR
   LMP-168075F                             TGATTAGCTAAGGCATTCCCA                                 
                                                                                                 
  *EBNA-2 primers*                                                                      
   EBNA-2-48810F                           AGGGATGCCTGGACACAAGA                              1st PCR
   EBNA-2-49411R                           TGTGCTGGTGCTGCTGGTGG                                  
   EBNA-2-1-F[a](#t4-fn2){ref-type="fn"}   TCTTGATAGGGATCCGCTAGGATA                          2nd PCR
   EBNA-2-1-R[a](#t4-fn2){ref-type="fn"}   ACCGTGGTTCTGGACTATCTGGAC                              
   EBNA-2-2-F[b](#t4-fn3){ref-type="fn"}   CATGGTAGCCTTAGGACATA                              2nd PCR
   EBNA-2-2-R[b](#t4-fn3){ref-type="fn"}   AGACTTAGTTGATGCCCTAG                                  

Abbreviations: EBV, Epstein--Barr virus; EBNA-1, EBV nuclear antigen 1; LMP, latent membrane protein.

EBNA-2 type 1 EBV yields a 497 bp product.

EBNA-2 type 2 EBV yields a 162 bp product.
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